DR. MARY KATHLEEN MCTIGUE, M.D.

Plain English
This study looked at how a protein called Protein Kinase A (PKA) works at specific contact points between cells and their surroundings, known as focal adhesions. The researchers found that PKA is active in these areas and identified 53 proteins that may be affected by PKA. They confirmed that tensin-3, which helps cells move, is one of these proteins that PKA directly influences. Understanding this can help improve our knowledge of how cells communicate and move, which is important for processes like wound healing and cancer spread. Who this helps: This research benefits scientists and medical professionals working on cell movement and treatments for diseases related to cell behavior.

Plain English
This study examined how a protein called PKA is involved in focal adhesions, which are important for how cells stick to their surroundings and move. The researchers found that PKA is active in these areas and identified 53 potential proteins it affects, with one of them being tensin-3, which helps regulate cell movement. Understanding how PKA influences these processes is important because it can lead to better insights into cell behavior in various medical conditions. Who this helps: This helps patients with conditions related to cell movement, such as cancer and wound healing.

Plain English
Researchers developed a new cancer drug called PF-07265028, which targets a specific enzyme called HPK1 that plays a role in the immune response against tumors. In trials, this drug was shown to be effective and safe enough to move to phase 1 testing on patients, with careful attention given to how it's broken down in the body and to ensure it specifically targets HPK1 without affecting similar enzymes. This discovery is important because it represents a new potential treatment option for cancer that uses the body's immune system to fight the disease. Who this helps: This helps cancer patients looking for new treatment options.

Plain English
This study focused on developing new drugs that target a protein called HPK1, which can suppress the immune response against cancer. Researchers created promising compounds called 5-amino-6-aryl pyrrolopyrimidine inhibitors, improving their effectiveness through careful design and testing. These new drugs could enhance the immune system's ability to fight cancer, which matters because they could lead to better treatment options for patients. Who this helps: This helps cancer patients seeking more effective therapies.

Plain English
This study looked at a new cancer treatment called PF-06939999, which targets a protein called PRMT5 that is often overactive in non-small cell lung cancer (NSCLC). Researchers found that this drug can slow down the growth of cancer cells and affects certain genetic processes causing the disease. Specifically, it reduced a type of protein linked to cancer growth and led to changes in gene expression, suggesting that it might work well in patients with specific genetic mutations. Who this helps: This benefits patients with non-small cell lung cancer, particularly those with certain genetic alterations.

Plain English
This study focused on developing a new drug called PF-06873600 that targets specific enzymes (CDK2, CDK4, and CDK6) involved in cancer cell growth. Researchers found that this drug could effectively inhibit these enzymes while being selective enough to avoid unwanted effects on a similar enzyme (CDK9). This discovery is important because it could help treat various types of cancer, especially in patients whose tumors no longer respond to existing treatments. Who this helps: This benefits cancer patients, particularly those with tumors resistant to current therapies.

Plain English
This study investigated a new drug, PF-06873600, that targets specific proteins (CDK2, CDK4, CDK6) involved in cancer cell growth to overcome resistance to an existing treatment for breast cancer called palbociclib. The researchers found that PF-06873600 works effectively in different cancer models and does not interfere with the immune system’s ability to fight tumors. This development is important because it offers hope for breast cancer patients who do not respond to current treatments, potentially improving their outcomes. Who this helps: Patients with breast cancer who have not benefited from existing CDK4/6 inhibitors.

Plain English
Researchers studied how a specific protein called HPK1 changes shape when affected by a drug called sunitinib. They found that HPK1 can exist in different forms: in one state, it does not work properly, while in another, it is fully active; these changes happen when HPK1's parts move around significantly. This is important because better understanding how to block HPK1 may improve the effectiveness of cancer treatments by boosting the immune response against tumors. Who this helps: This helps cancer patients who could benefit from enhanced immune treatments.

Plain English
This study looked at whether it’s possible to link ambulance records to emergency department records in the UK without using any personal information. Researchers found that they could successfully connect 81% of ambulance records to emergency department records across 13 hospitals, although it took an average of 65 weeks to do so. This is important because linking these records can help improve healthcare delivery by providing better data for patient care and treatment. Who this helps: This benefits hospitals, healthcare providers, and patients by enhancing data sharing and improving emergency care.

Plain English
This study focused on a protein called ALK, which can become cancerous when it mutates. Researchers found that certain mutations (ALK-C1156Y and ALK-L1196M) lead to increased movement within the protein, making it more active, whether it's chemically modified or not. This is important because understanding how these mutations affect ALK's behavior can help in developing better treatments for cancers caused by faulty ALK proteins. Who this helps: This benefits cancer patients who have ALK-related tumors.

Plain English
This study looked at how two cancer drugs, crizotinib and lorlatinib, interact with specific proteins involved in cancer, namely the c-ros oncogene 1 and anaplastic lymphoma kinase (ALK) L1196M. The researchers found that when these drugs bind to the proteins, they can stabilize nearby areas, which could affect how effectively the drugs work. Understanding these interactions is important because it helps improve the design of future cancer treatments. Who this helps: This helps patients with specific types of cancer by potentially leading to better drug options.

Plain English
Researchers studied a patient with a specific type of lung cancer who initially stopped responding to the drug crizotinib due to a mutation in her cancer. They found that while a new mutation made her cancer resistant to another treatment called lorlatinib, it unexpectedly allowed her cancer to respond to crizotinib again. After restarting crizotinib, her symptoms and liver issues improved significantly. Who this helps: This helps patients with ALK-positive lung cancer who have developed drug resistance.

Plain English
Researchers studied a type of leukemia that is resistant to many treatments due to a specific mutation called T315I. They found that a drug called axitinib effectively targets this mutation, reducing T315I-positive leukemia cells in a patient’s bone marrow quickly. This is significant because it offers a new treatment option for patients with this difficult-to-treat mutation, who currently have limited choices. Who this helps: This helps patients with T315I-mutant chronic myeloid leukemia.

Plain English
This study looked at a new drug called PF-06463922, which targets specific cancer-causing mutations related to ROS1 and ALK genes, especially in patients who have become resistant to an existing treatment called crizotinib. Researchers found that PF-06463922 was highly effective, showing strong results in lab tests against various ROS1 mutations, including those that made crizotinib less effective. This drug's ability to penetrate the central nervous system also makes it important for treating brain tumors linked to these mutations. Who this helps: This benefits patients with ROS1 fusion-positive cancers, particularly those who have not responded to previous treatments.

Plain English
Researchers studied how to develop stronger drugs to treat patients whose cancer no longer responds to crizotinib, a medication used for specific lymphoma types. They created a new drug called aminopyridine 8e that worked well against various ALK mutations, showing strong effectiveness in lab tests, including a significant ability to stop tumor growth in resistant cell lines. This matters because many patients with these mutations face ongoing disease, and better treatment options are needed. Who this helps: Patients with lymphoma who have developed resistance to crizotinib.

Plain English
Researchers developed a new drug called PF-06463922, which aims to treat patients with a specific type of lung cancer that is usually resistant to current treatments. This drug showed strong effectiveness against several cancer mutations, including those that make existing therapies less effective, and it can reach the brain, which is important since some cancer spreads to that area. The study found that PF-06463922 works well against both the original cancer and resistant forms, positioning it as a valuable option for improving patient outcomes. Who this helps: This helps lung cancer patients, especially those whose cancers have become resistant to other treatments.

Plain English
This study looked at how some lung cancer patients develop resistance to a drug called crizotinib, which is used to treat tumors with a specific genetic change known as ROS1 translocation. The researchers found that in one patient who initially responded well to the treatment, a new mutation made the cancer resistant; this mutation was found at all tumor sites examined after the patient's death. Understanding these mutations matters because it can help develop better treatment strategies for patients who stop responding to current drugs. Who this helps: This helps lung cancer patients and their doctors.

Plain English
Researchers studied a new drug called PF-04254644, which was designed to target cancer-related signaling but also affected heart function. In tests with rats, the drug caused an increase in heart rate and changes that led to heart muscle damage, leading to it being dropped from further development. This is important because it highlights the risks of heart-related side effects in drugs meant to treat cancer. Who this helps: This helps doctors and researchers learn about safety concerns in cancer drug development.

Plain English
This study examined how the density of cells in a lab dish and the presence of pyruvate, a common additive, influence the levels of harmful oxygen molecules that can damage cells. Researchers found that higher cell density helps protect against these harmful molecules and that pyruvate can help reduce their levels too—confirming that pyruvate is effective in lowering oxidative stress in cells. This is important because consistent and reliable lab results are crucial for understanding biological processes and developing new drugs. Who this helps: This helps researchers and scientists involved in drug development and testing.

Plain English
This study focused on a new cancer treatment called PF-04217903, which specifically targets a protein known as c-Met that is involved in tumor growth and spread. Researchers found that PF-04217903 was more than 1,000 times more selective for c-Met than other similar proteins, and it was effective in slowing down tumor growth in lab models, achieving up to 77% reduction in certain combinations. Understanding how PF-04217903 works is important because it could lead to better treatments for cancers that rely on the c-Met pathway. Who this helps: This helps patients with c-Met-related cancers.

Plain English
Researchers developed a new drug called PF-04217903 that specifically targets a protein involved in cancer growth, known as c-MET. In laboratory tests, this drug was found to effectively inhibit tumor growth in models where cancer relies on c-MET, showing it has strong effectiveness and good safety. This is important because it could lead to better treatments for certain cancers with fewer side effects. Who this helps: This helps cancer patients whose tumors depend on c-MET.

Plain English
This study looked at how different versions of drugs that target the VEGF receptor (used to treat certain types of cancer) work in the body. The researchers found that these drugs have different strengths and effectiveness based on their specific molecular structures. For example, some drugs are more efficient and better tolerated, leading to safer use in patients. This is important because understanding these differences can help design better cancer treatments that perform well in real-world settings. Who this helps: Patients fighting cancer, particularly those with renal cell carcinoma.

Plain English
Researchers studied a drug called crizotinib, which targets two important cancer-related proteins known as c-MET and ALK. They found that crizotinib is effective at blocking these proteins, which helps stop tumor growth. In laboratory tests, crizotinib showed strong results, significantly reducing tumor size. Who this helps: This benefits cancer patients, particularly those with tumors driven by c-MET and ALK.

Plain English
This study looked at whether sorafenib, a cancer treatment drug, can help prevent liver cancer from coming back after a liver transplant. The researchers found that only 12.5% of patients treated with sorafenib experienced a recurrence of cancer, compared to 50% of patients who did not receive the drug. Additionally, people on sorafenib had better survival rates—85.7% remained free of cancer after one year compared to 57.1% for those not taking the drug. Who this helps: This benefits liver transplant patients at high risk for liver cancer recurrence.

Plain English
This study examined how specific genetic mutations in gastrointestinal stromal tumors (GISTs) make them resistant to two cancer drugs, imatinib and sunitinib. Researchers found that when patients on imatinib develop secondary mutations, it often makes their cancer unresponsive to treatment; specifically, the D816H mutation is particularly resistant to sunitinib, which works against some other resistant types. Understanding these mechanisms is important because it helps researchers find ways to overcome drug resistance in cancer treatment. Who this helps: This helps doctors and researchers in treating patients with gastrointestinal stromal tumors.

Plain English
This study looked at how certain DNA damage caused by radiation is repaired by specific enzymes in cells. Researchers found that the presence of an oxidized base affects one enzyme (Ape1) less than a missing base (abasic site), which can block the work of another enzyme (Ogg1) and increase the risk of harmful double strand breaks in DNA. This matters because understanding these processes can help improve treatments for radiation exposure and possibly lead to better cancer therapies. Who this helps: This helps patients undergoing radiation therapy and researchers working on cancer treatments.

Plain English
This research studied how electric fields in the active sites of certain enzymes affect their behavior, focusing on two types of enzymes called thiol- and selenol-subtilisins. The researchers found that, unlike expected, the electric fields in these enzymes did not show polarization in their active sites until mutations were made—specifically creating variations known as N155G and P225A—which resulted in a strongly polarized state. This finding is important because it enhances our understanding of enzymatic reactions, which can lead to improved enzyme design for industrial and medical applications. Who this helps: This helps researchers and scientists working on enzyme development.

Plain English
This study looked at how the immune system of rabbits and mice responded to different versions of a chemical agent designed for targeted cancer treatment. Researchers found that when mice were given the (S) and (R) forms of this agent, they produced antibodies against them, with significant immune responses observed at different doses. However, the same agents did not trigger a similar immune response in rabbits, which is important for understanding how these treatments might work safely in humans. Who this helps: This research benefits doctors and researchers developing targeted cancer therapies.

Plain English
This study looked at a new approach for delivering targeted radiation therapy to tumors in mice with cancer. Researchers found that a special antibody (2D12.5) combined with a radioactive substance (88Y) effectively targeted cancer cells, achieving a high concentration in the tumors (4.41% of tumor weight) compared to the blood (21 times higher), and the therapy showed a favorable safety profile. This is promising because it suggests that this method could improve treatment for cancer by focusing radiation exactly where it's needed while minimizing exposure to healthy tissues. Who this helps: This benefits cancer patients by offering a potentially more effective treatment option.

Plain English
This study looked at how well placed-tagged platelets worked in 10 patients, measuring their viability and how they traveled in the body. They found that about 36% of the platelets could be tagged successfully, with 64% to 76% remaining active in the bloodstream after 15 minutes to four hours. However, tracking these platelets using PET scans was difficult because of too much interference from surrounding blood, leading to poor image quality in many cases. Who this helps: This research helps doctors who are looking for better ways to track and treat blood clots.

Plain English
This study looked at a new method for imaging tumors in mice using specially designed molecules called Janus haptens. The researchers found that using Janus haptens led to much higher concentrations of the tumor-targeting agents in tumors, reaching about 7% per gram, compared to just 1.4% with regular haptens, making the imaging much clearer and more effective in detecting tumors. This is important because it could help doctors identify tumors more accurately and quickly, improving diagnosis and treatment planning. Who this helps: This helps patients by improving tumor detection and diagnosis.

Plain English
This study looked at a new way to use imaging techniques to find tumors in mice by using a two-step approach. First, a non-radioactive antibody is injected to target the tumor, which can take several days to settle in the tumor area, and then a radioactive marker is added for imaging just a few hours before the pictures are taken. This method allows for better tumor visualization while utilizing a short-lived radioactive substance. Who this helps: This benefits researchers and doctors working on tumor detection and treatment.

Plain English
This study explored how monoclonal antibodies can effectively carry radioactive agents used in cancer treatment. The researchers found that using 100 micrograms of a specific antibody significantly increased the amount of the radioactive treatment in tumors by 50 times after 24 hours and improved the concentration needed for effective treatment. This is important because it suggests a way to enhance the targeting of cancer therapies, making them more effective while minimizing exposure to healthy tissue. Who this helps: This helps cancer patients and their doctors by improving treatment accuracy and reducing side effects.

Plain English
This study looked at how a special type of treatment using monoclonal antibodies combined with radioactive particles could improve the way tumors are imaged in mice. Researchers found that using a method called a "chelate chase" significantly reduced the radiation dose to organs like the liver and spleen by up to 95%, helping to focus the treatment more on the tumors. This is important because it means safer and more effective imaging for patients with cancer. Who this helps: Patients with cancer undergoing imaging procedures.

Plain English
In this study, researchers looked at how quickly two types of substances labeled with a metal (111In) break down in mice. They found that after nine days, 50% of the 111In remained in mice without any treatment, but only 8% remained in those treated with a substance that helps remove excess metal. This discovery is important because it allows for better imaging and tracking of drugs in the body without interference from free metal that could skew results over time. Who this helps: This helps doctors and researchers working on drug therapies and imaging techniques.

Plain English
This study looked at how a specific type of antibody, called a monoclonal antibody, can be labeled with a radioactive substance to help visualize lymph nodes in mice. The researchers found that the labeled antibodies were effective at targeting lymph nodes, with an 85-95% success rate in attaching the radioactive material. This approach is important because it could improve how doctors locate and diagnose certain cancers and blood diseases, potentially leading to better treatment options. Who this helps: Patients with cancers that spread to lymph nodes and doctors looking for improved imaging techniques.

Plain English
This study looked at how specially designed antibodies can be used to carry metal-based substances for cancer detection and treatment. Researchers created antibodies that target a specific metal, indium, and found that these antibodies strongly prefer to bind to indium over other metals, boosting their effectiveness. This matters because it can improve how well drugs and diagnostic tools reach tumors compared to healthy tissue, potentially leading to better cancer therapies. Who this helps: This helps cancer patients and doctors involved in their treatment.

Plain English
This study looked at how different substances influence the activation of a key enzyme called tyrosine hydroxylase in nerve-like cells. Researchers found that various agents, such as nerve growth factor (NGF) and epidermal growth factor (EGF), can specifically trigger the phosphorylation of tyrosine hydroxylase, increasing its activity by 2 to 4 times. Understanding these mechanisms is important because they show how certain factors can naturally control enzyme activity in nerve cells, which could have implications for treatments related to nerve function. Who this helps: This benefits patients with nerve-related conditions and doctors treating these patients.

Plain English
Researchers studied how to improve tumor imaging by addressing the problem of too much blood background interfering with the images. They found that injecting specific antibodies before imaging dramatically reduced the blood background, with blood activity dropping to just 1/48 of normal levels while tumor concentration remained unchanged, improving the clarity of images. This method allows doctors to obtain clearer images of tumors much faster, enhancing diagnosis and treatment monitoring. Who this helps: This helps patients undergoing tumor imaging by providing clearer and faster results.

Plain English
This research focused on attaching special chemical agents to antibodies so they can bind with metal ions. The study found procedures to effectively create these attachments, showing that the modified antibodies remain effective in targeting specific antigens in experiments with mice. This is important because it could enhance the use of antibodies in medical imaging and treatment by allowing them to carry metal ions, which can improve their diagnostic and therapeutic capabilities. Who this helps: This benefits patients by improving diagnostic tests and treatments that use antibody-based therapies.

Plain English
This study looked at how sodium movement in the kidneys affects oxygen use in lab rats. Researchers found that when they changed pressure or used a specific chemical (ouabain), the efficiency of how sodium transport connected to oxygen consumption was lower than what has been seen in living rats, with ratios like 66.3 and 29.1 compared to an average of around 37.0 and 20.3 in different tests. These findings matter because they suggest that the way kidneys work in a lab setting may not accurately reflect how they function in real life, which could affect how we understand kidney efficiency and treatment. Who this helps: This helps doctors and researchers studying kidney function and treatment options.

Plain English
This study investigated how a chemotherapy drug called cis-platinum causes kidney damage in rats. Researchers found that after giving the rats a dose of the drug, levels of a substance linked to kidney health called sulfhydryl groups dropped significantly by 14% within 120 hours. This matters because it helps to understand the specific way cis-platinum harms the kidneys, which could lead to better protection for patients receiving this treatment. Who this helps: Patients undergoing chemotherapy with cis-platinum.

Plain English
This study focused on how the urinary bladders of Colombian toads transport chloride ions. Researchers found that removing potassium led to a change in electrical current related to chloride transport, but the amount of current didn’t directly link to how much chloride was actually transported. Additionally, stopping bicarbonate in the solutions also stopped the current, and using a drug called acetazolamide reduced both the current and the chloride transport. Who this helps: This research can help scientists and doctors understand how ion transport works in bladder tissues, which could have implications for treating bladder-related issues.

Plain English
Researchers studied pocket mice to see how they would handle high levels of oxygen and heat during the Apollo XVII mission. They found that the mice could survive normal temperatures with high oxygen levels for up to seven days, but some did not survive longer exposures to high oxygen and heat. This matters because it shows that pocket mice can endure the conditions they would face in space, which helps scientists prepare for future missions. Who this helps: This helps researchers and astronauts preparing for space travel.